Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung City, 404332, Taiwan (ROC).
School and Medicine, China Medical University, Taichung, Taiwan (ROC).
Int J Hematol. 2023 Jan;117(1):149-152. doi: 10.1007/s12185-022-03445-2. Epub 2022 Sep 4.
Global vaccination against the coronavirus disease 2019 (COVID-19) is thought to be the most effective way to end or at least contain the COVID-19 pandemic. However, despite the good safety profiles and effectiveness of the available COVID-19 vaccines, rare but serious hematological complications have emerged, including thromboembolic outcomes with thrombocytopenia following the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and Ad26.COV.2.S (Johnson & Johnson/Janssen) vaccines. Moreover, COVID-19 vaccination may be linked to the development of aplastic anemia (AA). We discuss four cases of AA that arose after COVID-19 vaccination in our hospital and two other such cases identified in our literature review.
全球接种 2019 年冠状病毒病（COVID-19）疫苗被认为是结束或至少控制 COVID-19 大流行的最有效方法。然而，尽管现有 COVID-19 疫苗具有良好的安全性和有效性，但仍出现了罕见但严重的血液学并发症，包括 ChAdOx1 nCoV-19（牛津-阿斯利康）和 Ad26.COV.2.S（强生/杨森）疫苗接种后伴血小板减少的血栓栓塞结局。此外，COVID-19 疫苗接种可能与再生障碍性贫血（AA）的发生有关。我们在本院讨论了 4 例 COVID-19 疫苗接种后出现 AA 的病例，并在文献复习中发现了另外 2 例此类病例。
